Skip to main content

Table 3 Sub-analysis compared with the baseline CWRET

From: The impact of high-flow nasal cannula oxygen therapy on exercise capacity in fibrotic interstitial lung disease: a proof-of-concept randomized controlled crossover trial

 

Mean

95% CI

P-value*

Endurance time, min

 Baseline test

3.9

1.7–6.2

Ref.

 VM

7.6

5.3–9.8

0.076

 HFNC

6.8

4.6–9.0

0.226

Min SpO2, %

 Baseline test

77.7

73.8–81.6

Ref.

 VM

89.4

85.5–93.3

<  0.001

 HFNC

89.7

85.8–93.5

< 0.001

Max HR, bpm

 Baseline test

121.2

113.2–129.1

Ref.

 VM

124.2

116.2–132.1

1.000

 HFNC

120.8

112.8–128.8

1.000

Isotime Borg scale (dyspnea)

 Baseline test

6.6

5.4–7.7

Ref.

 VM

4.5

3.4–5.6

0.040

 HFNC

3.9

2.8–5.1

0.006

Isotime Borg scale (leg fatigue)

 Baseline test

6.0

4.7–7.3

Ref.

 VM

4.3

3.0–5.6

0.188

 HFNC

3.7

2.4–4.9

0.035

Final Borg scale (dyspnea)

 Baseline test

6.9

5.8–7.9

Ref.

 VM

7.0

5.9–8.0

1.000

 HFNC

6.6

5.5–7.7

1.000

Final Borg scale (leg fatigue)

 Baseline test

6.2

4.7–7.6

Ref.

 VM

6.4

5.0–7.8

1.000

 HFNC

6.3

4.9–7.7

1.000

  1. *Calculated by generalized linear mixed-effects model with fixed factors for each device, sequence, and period, and a random factor for subject within sequence. The Bonferroni post-hoc test was performed for multiple comparisons of groups